## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: Shiao, Rei Tsang

NAZARE, et al.

Art Unit: 1626

Application No.: 10/849,089

Filed: May 19, 2004

Title: Azaindole-derivatives as factor Xa inhibitors

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

 $\boxtimes$ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first. П The undersigned attorney certifies that each item of information contained in this (1)Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or  $\boxtimes$ (3) This Information Disclosure Statement is accompanied by payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized. Respectfully submitted,

> Jiang Lin, Reg. No. 51,065 Attorney/Agent for Applicant

Dated

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800

Feb. 22, 2007

Telephone (908) 231-**3582** Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2003/0033 US NP

Please type a plus sign (+) inside this box	-	. 4
riease type a plus sign (+) maide this box	-	v

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitu	te for form 1449A/P	то		Complete if Known			
15154			201 001175	Application Number 10/849,089			
			SCLOSURE	Filing Date	05-19-2004		
STA	TEMENT	BY A	APPLICANT	First Named Inventor	NAZARÉ, et al.		
				Group Art Unit	1626		
	(use as many st	heets as	s necessary)	Examiner Name	SHIAO, Rei Tsang		
Sheet	1	of	1	Attorney Docket Number	DEAV2003/0033 - US - NP		

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Document  Number  Kind Code <sup>2</sup> (if known)		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		7,135,469		Donald J. PINTO	11-14-2006		
						· · · · · · · · · · · · · · · · · · ·	
				•			
		l					
				•			
				-			

	FOREIGN PATENT DOCUMENTS							
	Cite No.1	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	T
		Office <sup>3</sup>	Number⁴	Kind Code <sup>5</sup> ( <i>if known</i> )	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
								T
					· · · · · · · · · · · · · · · · · · ·			<u> </u>
igsqcut		ļ <b>.</b>			•			ـــــ

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.





<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.